Posts filtered on Category

Category: Denosumab

Amgen said that a highly-anticipated study of Denosumab, its treatment for bone loss, showed that the therapy reduced the incidence of new vertebral, non-vertebral, and hip fractures, compared to a placebo in 7,800 women with postmenopausal osteoporosis. …

Amgen issued a press release this morning announcing that Nplate, its treatment for Idiopathic thrombocytopenic purpura, a rare bleeding disorder, had been approved, only to retract it later. In the follow-up release, Amgen said the “release was issued prematurely by Business Wire.” …

When I last wrote about Amgen’s Denosumab (the company’s best hope for another blockbuster) I mentioned that an oncology team in Seattle had been working on the drug’s development for the last 13 years. …

On Wednesday, I described the results of Amgen’s latest Denosumab trial as “positive.” After all, in the phase three study of 332 women, the therapy — which is being developed partly at Amgen’s Helix campus — increased bone mineral density throughout the skeleton, while the incidence of side effects was the same in patients taking the therapy and those taking a placebo. …

A study of Denosumab, the therapy that Amgen hopes will be its next blockbuster and is being developed partly at the company’s Seattle Helix campus, showed that the treatment increased bone mineral density in women with early- and late-stage postmenopausal osteoporosis, the company said Wednesday. …

Blog Search

Keyword search across all the entries in this blog.

Browse previous blog posts by month and year of entry. You'll see all the posts for that time period.

Select Month

Show Earlier

Browse previous blog posts by month and year of entry. You'll see all the posts for that time period.